Measuring Sleep Impact

EP: 1.Exploring Long-Term Data and Combination Therapies

EP: 2.Rethinking Itch Severity in Atopic Dermatitis

EP: 3.Understanding Long-Term Safety, Efficacy, and Demographic Variances in Ruxolitinib Trials

Now Viewing

EP: 4.Measuring Sleep Impact

EP: 5.Observing BSA Changes and Inflammation Resolution

EP: 6.Assessing Quality of Life and AAD Research Considerations

EP: 7.Comparing the Landscape of Topicals

EP: 8.Utilizing Multidisciplinary Solutions for Itch

EP: 9.Pediatric Potency: Ruxolitinib vs Triamcinolone

EP: 10.Remaining Research Gaps and Bright Future in AD

In this Dermatology Times Expert Perspectives series, 5 experts delve into the multifaceted aspects of pediatric atopic dermatitis care including demographic variances to long-term safety and efficacy, comparative analyses, key takeaways from recent research, personalized approaches, and future research directions. Discover clinical insights into the role of ruxolitinib (Opzelura) in addressing critical challenges and enhancing patient outcomes.

In this episode, Alexandra Golant, MD, assistant professor and residency program director at the Icahn School of Medicine at Mount Sinai in New York, New York, shares how sleep improvement is measured and the difference an effective treatment makes for the patient’s entire family.

Episode Transcript

Golant: Given what we know about the rapid onset of itch reduction for the use of topical ruxolitinib for our pediatric AD populations in these trials, it's really unsurprising that we see significant improvements in quality of life outcome measures when you look at Patient Oriented Eczema Measure (POEM) [and] when you look at Dermatology Life Quality Index (DLQI) scores in these patients. I think a large part of that is the itch reduction, allowing patients to sleep more comfortably.
I often say that AD, particularly when a child has AD, it becomes really a family disease. It becomes a family experience if you have or if you know a young child when a child is not sleeping. It's not just the child that's up at night. It's sometimes 1 or both parents, sometimes siblings. So, improving itch and really been able to improve that quality of life for these young patients is an incredible outcome of any therapy, including what we see here with with ruxolitinib.